Corbus Pharmaceuticals recently announced that the company’s Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) is now open and has received clearance to initiate a Phase 2 clinical study with Resunab to address treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma.
Corbus Pharmaceuticals is a clinical stage bio-pharmaceutical company committed to advancing research on life-threatening, rare and chronic inflammatory diseases. The company intends to initiate the Phase 2 study in the 2nd quarter of 2015. Corbus also plans to submit in the second quarter of 2015 a Phase 2 protocol under this current IND to test Resunab as a treatment for cystic fibrosis.
Scleroderma is a systemic autoimmune disease that is characterized by the hardening of the skin and that can also affect internal organs such as the lungs. Cystic fibrosis is a genetic disorder that affects the lungs, causing difficulties in breathing and resulting in lung infections.
Corbus Pharmaceuticals’ Resunab
Resunab™ is an oral anti-inflammatory drug to address inflammation. When a chronic inflammatory disease occurs, the body is not able to turn off heightened inflammatory responses. Resunab has the potential to act as a safe and strong anti-inflammatory drug that features a unique mechanism that addresses inflammation and might treat several chronic inflammatory diseases.
Corbus Pharmaceuticals Holding, Inc., also recently presented its financial results for 2014. The company is continuing efforts to bring their lead product candidate Resunab to market as a treatment for cystic fibrosis (CF) and diffuse cutaneous systemic sclerosis (scleroderma). The company was also present at last month’s 17th Annual BIO CEO & Investor Conference, presenting its latest research on Resunab.